Leaderboards/Treatment of Major Depression

Treatment of Major Depression

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Papers

Major depressive disorder: hypothesis, mechanism, prevention and treatment

Signal Transduction and Targeted Therapy|2024

905 cit.

Publication in Depression and Anxiety (2025) [53 citations, W4409825692]

Depression and Anxiety|2025

53 cit.

Publication in Molecular Psychiatry (2024) [44 citations, W4390579790]

Molecular Psychiatry|2024

44 cit.

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study

The International Journal of Neuropsychopharmacology|2025

30 cit.

Publication in Nature Medicine (2025) [29 citations, W4412640246]

Nature Medicine|2025

29 cit.

Publication in Neuropsychopharmacology (2025) [12 citations, W4408518934]

Neuropsychopharmacology|2025

12 cit.

Publication in BJPsych Open (2024) [7 citations, W4396807237]

BJPsych Open|2024

7 cit.

Publication in Neuron (2025) [4 citations, W4415063260]

Neuron|2025

4 cit.

Publication in Journal of Neurophysiology (2024) [3 citations, W4404586024]

Journal of Neurophysiology|2024

3 cit.

Publication in American Journal of Psychiatry (2026) [2 citations, W7147487753]

American Journal of Psychiatry|2026

2 cit.

Emerging Leaders

Drafting the new consensus

Papers

Comparing network structures on three aspects: A permutation test.

Psychological Methods|2022

1.3k cit.

Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta‐analysis including 409 trials with 52,702 patients

World Psychiatry|2023

311 cit.

Randomized Trial of a Generative AI Chatbot for Mental Health Treatment

NEJM AI|2025

205 cit.

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin

Med|2024

93 cit.

Guided internet-based transdiagnostic individually tailored Cognitive Behavioral Therapy for symptoms of depression and/or anxiety in college students: A randomized controlled trial

Behaviour Research and Therapy|2022

63 cit.

Digital phenotyping of generalized anxiety disorder: using artificial intelligence to accurately predict symptom severity using wearable sensors in daily life

Translational Psychiatry|2022

63 cit.

The Challenges in Designing a Prevention Chatbot for Eating Disorders: Observational Study

JMIR Formative Research|2022

53 cit.

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data

Journal of Affective Disorders|2023

52 cit.

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)

Cancers|2023

49 cit.

Depressive symptoms as a heterogeneous and constantly evolving dynamical system: Idiographic depressive symptom networks of rapid symptom changes among persons with major depressive disorder.

Journal of Psychopathology and Clinical Science|2024

49 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

Unknown

The University of Texas Southwestern Medical Center

Carlos A. Zarate

National Institute of Mental Health

Unknown

Southwestern Medical Center

Husseini K. Manji

National Institutes of Health

Mark A. Lau

Institute of Flight

Papers

A New Depression Scale Designed to be Sensitive to Change

The British Journal of Psychiatry|1979

13.9k cit.

Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

American Journal of Psychiatry|2006

5.5k cit.

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

Biological Psychiatry|2003

3.9k cit.

Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice

American Journal of Psychiatry|2006

3.9k cit.

Antidepressant effects of ketamine in depressed patients

Biological Psychiatry|2000

3.8k cit.

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

Archives of General Psychiatry|2006

3.8k cit.

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans

Archives of General Psychiatry|1994

3.3k cit.

Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus

Journal of Neuroscience|2000

3.1k cit.

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Science|2010

2.9k cit.

Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.

Journal of Consulting and Clinical Psychology|2000

2.6k cit.

Reagents for Treatment of Major Depression

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

Bak (D4E4) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 350 Conjugate)

#17316$458

View Evidence →

Cell Signaling TechnologyEvidence 68

Nucleolin (E5M7K) Mouse Monoclonal Antibody

#87792$156,345

View Evidence →

Cell Signaling TechnologyEvidence 60

TrkB (80E3) Rabbit Monoclonal Antibody

#4603$148,348

View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

Coronin 1A (D6K5B) Rabbit Monoclonal Antibody (Alexa Fluor® 647 Conjugate)

Cited in 14 papers

#65356$465

View Evidence →

Cell Signaling TechnologyEvidence 65

GATA-4 (D3A3M) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 350 Conjugate)

Cited in 10 papers

#31948$458

View Evidence →

Cell Signaling TechnologyEvidence 64

MZB1 (E8V4N) Rabbit Monoclonal Antibody

Cited in 5 papers

#96905$161,351

View Evidence →